You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Omalizumab reduced inhaled corticosteroid use and exacerbations in childhood allergic asthma

https://doi.org/10.1136/ebm.7.1.12

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) Pediatrics 108, e36. Milgrom H, Berger W, Nayak A. , et al. . Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).. Aug;. :. ..
    OpenUrlAbstract/FREE Full Text

    
 
 QUESTION: In children with moderate to severe allergic asthma who require daily inhaled corticosteroid (ICS) treatment, is omalizumab (anti-immunoglobulin E [anti-IgE] antibody) more effective than placebo for reducing steroid use and asthma exacerbations?

    Design

    Randomised {allocation concealed*}†, blinded (clinicians, patients {outcome assessors, and statisticians}†,)* placebo controlled trial with 34 weeks of follow up.

    Setting

    Research centres in 12 US states and in Washington, DC.

    Patients

    334 asthmatic patients who were 6 to 12 years of age (mean age 9 y, 69% boys) and whose asthma was well controlled with ICSs (beclomethasone dipropionate [BDP] and bronchodilator treatment) for ≥ 3 months before randomisation. Other inclusion criteria were allergic asthma for ≥ 1 year; positive skin prick test result to ≥ 1 of house dust mite, cockroach, dog, or cat; total serum IgE level between 30 …

    View Full Text